Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Accendra Health, Inc.NYSE: ACH

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 0.0% of revenue for ACH, versus a peer median of 19.0%.
ACH Competitors
Research & Development for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CABACabaletta Bio, Inc.LTM Mar 2026$151.01M USD+44.8%+53.7%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$129.09M USD-32.1%-16.3%—
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M USD+36.9%+34.3%807.2%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M USD-62.3%-19.9%171.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
OMOutset Medical, Inc.LTM Mar 2026$21.34M USD-31.8%-24.3%18.1%
SGHTSight Sciences, Inc.LTM Mar 2026$12.72M USD-28.5%-13.9%16.0%
CVRXCVRx, Inc.LTM Mar 2026$11.7M USD+10.5%+3.8%19.8%
ACHAccendra Health, Inc.LTM Mar 2026$0 USD——0.0%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD-100.0%—0.0%
HITIHigh Tide Inc.LTM Apr 2026CA$0 CAD——0.0%
Peer median (excluding ACH) —-28.5%-13.0%19.0%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.